Home Blood Glucose Monitoring in Non‐insulin‐dependent Diabetics: The Effect of Gliclazide on Blood Glucose and Weight Control, a Multicentre Trial
Kenneth M Shaw, M S Wheeley, David B. Campbell, J. D. Ward
Abstract
Kenneth M Shaw, M S Wheeley, David B. Campbell, J. D. Ward
Abstract
The efficacy of the sulphonylurea gliclazide was assessed in 229 non-insulin-dependent diabetics attending U.K. outpatient diabetic clinics. Patients inadequately controlled by diet alone or oral hypoglycaemic agents used reflectance meters to monitor their blood glucose. After a 4-week run-in, in those whose control remained unsatisfactory, gliclazide was either added to diet, or given in place of existing drugs. Patients continued home-monitoring and were followed for 3 months. Gliclazide reduced mean random blood glucose in all groups, particularly those previously treated by diet alone or a first-generation sulphonylurea. The patients improved in their ability to measure glucose at home and within 2 months a good correlation with laboratory measurements was found. Mean body weight was reduced, particularly in obese and elderly subjects and those treated previously with sulphonylurea drugs. Side effects were mild and only two patients were withdrawn for this reason.
OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The efficacy of the sulphonylurea gliclazide was assessed in 229 non-insulin-dependent diabetics attending U.K. outpatient diabetic clinics. Patients inadequately controlled by diet alone or oral hypoglycaemic agents used reflectance meters to monitor their blood glucose. After a 4-week run-in, in those whose control remained unsatisfactory, gliclazide was either added to diet, or given in place of existing drugs. Patients continued home-monitoring and were followed for 3 months. Gliclazide reduced mean random blood glucose in all groups, particularly those previously treated by diet alone or a first-generation sulphonylurea. The patients improved in their ability to measure glucose at home and within 2 months a good correlation with laboratory measurements was found. Mean body weight was reduced, particularly in obese and elderly subjects and those treated previously with sulphonylurea drugs. Side effects were mild and only two patients were withdrawn for this reason.
Key concepts: Medicine, Gliclazide, Diabetes mellitus, Insulin, Internal medicine, Body weight, Endocrinology, Outpatient clinic